Paper · 29675723

Intratumoral Heterogeneity of SMAD4 Immunohistochemical Expression and Its Role in Prediction of Recurrence Pattern in Patients with Resectable Pancreatic Cancer.

Pokataev I and 9 others. J Gastrointest Cancer, 2019. Cited by 4 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Intratumoral Heterogeneity of SMAD4 Immunohistochemical Expression and Its Role in Prediction of Recurrence Pattern in Patients with Resectable Pancreatic Cancer. Papers, record 29675723. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29675723

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Intratumoral Heterogeneity of SMAD4 Immunohistochemical Expression and Its Role in Prediction of Recurrence Pattern in Patients with Resectable Pancreatic Cancer.; PubMed
Journal: J Gastrointest Cancer; PubMed
Year: 2019; PubMed
Publication types: Journal Article; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/29675723/; PubMed
DOI: https://doi.org/10.1007/s12029-018-0103-6; PubMed
The journal: https://conductscience.org/library/journal-index/101479627; PubMed
Citations, by iCite: 4; iCite
Relative citation ratio, by iCite: 0.15; iCite
Revised in PubMed: 2020-02-25; PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Pokataev I	Ilya	https://orcid.org/0000-0001-9864-3837
2	Kudaibergenova A	Asel
3	Artemyeva A	Anna
4	Popova A	Anna
5	Rumyantsev A	Alexey
6	Podluzhny D	Danil
7	Kudashkin N	Nikolay
8	Fedyanin M	Mikhail
9	Tryakin A	Alexey
10	Tjulandin S	Sergey

Source PubMed

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Adenocarcinoma	Major topic
Biomarkers, Tumor	Major topic
Carcinoma, Pancreatic Ductal	Major topic
Neoplasm Recurrence, Local	Major topic
Pancreatic Intraductal Neoplasms	Major topic
Pancreatic Neoplasms	Major topic
Smad4 Protein	Major topic
Adult
Aged
Female
Follow-Up Studies
Humans
Lymphatic Metastasis
Male
Middle Aged
Neoplasm Invasiveness
Pancreatectomy
Prognosis
Retrospective Studies
Survival Rate

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References17

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	10,615,932	Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.	Ann Surg	1999	https://conductscience.org/library/papers/10615932	PubMed
2	15,028,824	A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.	N Engl J Med	2004	https://conductscience.org/library/papers/15028824	PubMed
3	15,154,643	The dissociated expression of protein and messenger RNA of DPC4 in human invasive ductal carcinoma of the pancreas and their implication for patient outcome.	Anticancer Res	2004	https://conductscience.org/library/papers/15154643	PubMed
4	16,489,022	The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.	Cancer Res	2006	https://conductscience.org/library/papers/16489022	PubMed
5	17,723,364	Advances in cancer tissue microarray technology: Towards improved understanding and diagnostics.	Anal Chim Acta	2006	https://conductscience.org/library/papers/17723364	PubMed
6	19,273,710	DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.	J Clin Oncol	2009	https://conductscience.org/library/papers/19273710	PubMed
7	20,837,948	Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.	J Clin Oncol	2010	https://conductscience.org/library/papers/20837948	PubMed
8	21,709,185	Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.	J Clin Oncol	2011	https://conductscience.org/library/papers/21709185	PubMed
9	23,008,325	Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.	J Clin Oncol	2012	https://conductscience.org/library/papers/23008325	PubMed
10	23,360,922	Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression.	Ann Surg	2013	https://conductscience.org/library/papers/23360922	PubMed

1 to 10 of 17

See all 17 references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMID	Title	Journal	Year	In Papers	Source
42,979,207	Liver-Lung Organotropism in Pancreatic Ductal Adenocarcinoma: A Five-Stage Framework.	Cancer Manag Res	2026	https://conductscience.org/library/papers/42979207	PubMed
35,205,719	The Role of SMAD4 Inactivation in Epithelial-Mesenchymal Plasticity of Pancreatic Ductal Adenocarcinoma: The Missing Link?	Cancers (Basel)	2022	https://conductscience.org/library/papers/35205719	PubMed
34,790,392	Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy.	J Gastrointest Oncol	2021	https://conductscience.org/library/papers/34790392	PubMed

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes
SMAD4	4,089	PubTator's text mining	https://conductscience.org/library/genes/4089

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29675723

GET https://conductscience.org/api/papers/v1/29675723/authors

API reference For AI assistants